Clinical trial NCT03520075: Study of ASTX029 in Subjects With Advanced Solid Tumors
Official title: A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE1
PHASE2
Conditions: Solid Tumor, Adult
Keywords: Neoplasms
Solid Tumors
Antineoplastic Agents
MAPK
ERK
Lead sponsor: Taiho Oncology, Inc.
Sponsor class: INDUSTRY
First posted: 2018-05-09
Enrollment: 190
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is a first-in-human, open-label, multicenter, Phase 1-2 study to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of ASTX029 administered orally to subjects with advanced solid malignancies who are not candidates for approved or available therapies.

Detailed description: ASTX029 is a synthetic small molecule inhibitor of extracellular signal-regulated kinases (ERKs) 1/2. ASTX029 has not been previously evaluated in human subjects. The Phase 1 portion of this study will assess safety and determine the maximum tolerated dose, the recommended Phase 2 dose (RP2D), and the recommended dosing regimen of ASTX029 administered orally. The Phase 2 portion will assess preliminary clinical activity in tumors characterized by gene aberrations in the mitogen-activated protein kinase (MAPK) signal pathway that may confer sensitivity to ASTX029.

Eligibility criteria: Inclusion Criteria:

Subjects must fulfill all of the following inclusion criteria.

1. Able to understand and comply with study procedures, understand the risks involved in the study, and provide written informed consent before any study-specific procedure is performed.
2. Men or women 18 years of age or older.
3. Subjects with histologically or cytologically confirmed advanced solid tumors that are metastatic or unresectable, who are refractory or have relapsed after treatment with available therapies or for whom standard life-prolonging measures or approved therapies are not available. In Phase 1 Part B and in the Phase 2 portion of the protocol, subjects must also have documented gene alterations in the MAPK pathway as detailed in the protocol.
4. In Phase 1 Part B of the protocol, subjects must have disease lesions that are amenable to biopsy.
5. In the Phase 2 portion of the protocol, subjects must have measurable disease according to RECIST v1.1.
6. Eastern Cooperative Oncology Group performance status 0 to 2.
7. Acceptable organ function as evidenced by the following laboratory data:

   1. Aspartate aminotransferase (AST) and alanine aminotransferase ≤2×upper limit of normal (ULN) or ≤3 ULN in the presence of liver metastases.
   2. Total serum bilirubin ≤1.5×ULN.
   3. Absolute neutrophil count (ANC) ≥1500 cells/mm3.
   4. Platelet count ≥100,000 cells/mm3.
   5. Calculated creatinine clearance (by the standard Cockcroft Gault formula) of ≥50 mL/min or glomerular filtration rate of ≥50 mL/min.
8. Women of child-bearing potential (according to recommendations of the Clinical Trial Facilitation Group \[CTFG\]; see protocol for details) must not be pregnant or breastfeeding and must have a negative pregnancy test within 24 hours before the first dose of study treatment. While receiving study treatment and for at least 5 half-lives of ASTX029 or metabolite plus 30 days after completing treatment, women of child-bearing potential must agree to practice highly effective contraceptive measures (as described in the protocol) and must refrain from donating eggs (ova, oocytes) for the purpose of reproduction.
9. Men with female partners of child-bearing potential (according to recommendations of the CTFG; see protocol for details) must agree to, during the treatment period and for at least 5 half-lives of ASTX029 or metabolite plus 90 days after completing treatment, practice highly effective contraceptive measures (as described in the protocol), not to father a child, and to refrain from donating sperm.

Exclusion Criteria:

1. Hypersensitivity to ASTX029 or excipients of the drug product.
2. Poor medical risk in the investigator's opinion because of systemic diseases in addition to the cancer under study, for example, uncontrolled infections.
3. Life-threatening illness, significant organ system dysfunction, or other condition that, in the investigator's opinion, could compromise subject safety or the integrity of study outcomes or interfere with the absorption or metabolism of ASTX029.
4. Prior anticancer treatments or therapies within the indicated time window prior to first dose of study treatment (ASTX029), as follows:

   1. Cytotoxic chemotherapy or radiotherapy within 3 weeks prior. Palliative radiotherapy to a single lesion within 2 weeks prior. Any encountered treatment-related toxicities (excepting alopecia) not stabilized or resolved to ≤Grade 1.
   2. Monoclonal antibodies within 4 weeks prior. Any encountered treatment-related toxicities not stabilized or resolved to ≤Grade 1.
   3. Molecularly targeted drug or investigational drugs, without the potential for delayed toxicity, within 4 weeks of the first dose of study treatment or 5 half-lives (minimum 14 days), whichever is shorter. Any encountered treatment-related toxicities (excepting alopecia) not stabilized or resolved to ≤Grade 1.
5. Prior treatment with extracellular signal-regulated kinase (ERK) inhibitors.
6. History of, or at risk for, cardiac disease, as evidenced by 1 or more of the following conditions:

   1. Abnormal left ventricular ejection fraction (LVEF; \<50%) on echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan.
   2. Congestive cardiac failure of ≥Grade 3 severity according to New York Heart Association functional classification defined as patients with marked limitation of activity and who are comfortable only at rest.
   3. Unstable cardiac disease including unstable angina or hypertension as defined by the need for overnight hospital admission within the last 3 months (90 days).
   4. History or evidence of long QT interval corrected for heart rate (QTc), ventricular arrhythmias including ventricular bigeminy, complete left bundle branch block, clinically significant bradyarrhythmias such as sick sinus syndrome, second- and third-degree atrioventricular (AV) block, presence of cardiac pacemaker or defibrillator, or other significant arrhythmias.
   5. Screening 12-lead electrocardiogram (ECG) with measurable QTc interval of ≥470 msec. (Fridericia's formula should be used to calculate the QTc interval throughout the study.)
7. Known history of human immunodeficiency virus (HIV) infection or seropositive results consistent with active hepatitis B virus (HBV) or active hepatitis C virus (HCV) infection.
8. Known brain metastases, unless previously treated and stable for at least 3 months with or without steroids.
9. Known significant mental illness or other conditions, such as active alcohol or other substance abuse that, in the opinion of the investigator, predispose the subject to high risk of noncompliance with the protocol treatment or assessments.
10. History or current evidence/risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR) including:

    1. Presence of predisposing factors to RVO or CSR (eg, uncontrolled glaucoma or ocular hypertension, uncontrolled diabetes mellitus) or
    2. Visible retinal pathology as assessed by ophthalmic examination at screening that is considered a risk factor for RVO or CSR such as:

       * Evidence of optic disc cupping or
       * Evidence of new visual field defects on automated perimetry or
       * Intraocular pressure \>21 mmHg as measured by tonography.

Primary outcomes:
measure: Safety (Phase 1) - Dose-limiting toxicities including incidence of Treatment-Emergent Adverse Events
timeFrame: End of each dosing cycle (Day 21 of 21-day cycle)
measure: Efficacy (Phase 2) - Response Evaluation Criteria in Solid Tumors using RECIST v1.1
timeFrame: Baseline to measured progressive disease or start of new anticancer therapy, through study completion, an average of 6 months to 1 year
Secondary outcomes:
measure: Pharmacokinetic profile of ASTX029 - AUC
timeFrame: Day 1 and 2 of Cycle 1 and Cycle 2 for Regimen 1, and Day 1, 2, 14, and 15 of Cycle 1 for Regimen 2
measure: Pharmacokinetic profile of ASTX029 - Cmax
timeFrame: Day 1 and 2 of Cycle 1 and Cycle 2 for Regimen 1, and Day 1, 2, 14, and 15 of Cycle 1 for Regimen 2
measure: Pharmacokinetic profile of ASTX029 - Cmin
timeFrame: Day 1 and 2 of Cycle 1 and Cycle 2 for Regimen 1, and Day 1, 2, 14, and 15 of Cycle 1 for Regimen 2
measure: Pharmacokinetic profile of ASTX029 - Tmax
timeFrame: Day 1 and 2 of Cycle 1 and Cycle 2 for Regimen 1, and Day 1, 2, 14, and 15 of Cycle 1 for Regimen 2
measure: Pharmacokinetic profile of ASTX029 - Half-life
timeFrame: Day 1 and 2 of Cycle 1 and Cycle 2 for Regimen 1, and Day 1, 2, 14, and 15 of Cycle 1 for Regimen 2
measure: Pharmacokinetic profile of ASTX029 - Metabolites
timeFrame: Day 1 and 2 of Cycle 1 and Cycle 2 for Regimen 1, and Day 1, 2, 14, and 15 of Cycle 1 for Regimen 2
measure: Efficacy - DOR
timeFrame: Baseline to measured progressive disease or start of new anticancer therapy, through study completion, an average of 6 months to 1 year
measure: Efficacy - DCR
timeFrame: Baseline to measured progressive disease or start of new anticancer therapy, through study completion, an average of 6 months to 1 year
measure: Efficacy - PFS
timeFrame: Baseline to measured progressive disease or start of new anticancer therapy, through study completion, an average of 6 months to 1 year
measure: Efficacy - OS
timeFrame: Baseline to measured progressive disease or start of new anticancer therapy, through study completion, an average of 6 months to 1 year
measure: Target engagement in tumor tissues - pRSK
timeFrame: Day 8 of Cycle 2
Other outcomes:
Locations:
city: Duarte
country: United States
facility: City of Hope Comprehensive Cancer Center
state: California
city: Los Angeles
country: United States
facility: University of Southern California Norris Comprehensive Cancer Center Site#114
state: California
city: Los Angeles
country: United States
facility: Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute Site# 107
state: California
city: Newport Beach
country: United States
facility: Hoag Memorial Hospital Site#115
state: California
city: Sacramento
country: United States
facility: University of California Davis Medical Center Site #121
state: California
city: San Francisco
country: United States
facility: California Pacific Medical Center - Sutter Pacific Medical Center Site#117
state: California
city: New Haven
country: United States
facility: Smilow Cancer Hospital at Yale New Haven Site#105
state: Connecticut
city: Iowa City
country: United States
facility: Holden Comprehensive Cancer Center
state: Iowa
city: Baltimore
country: United States
facility: The Sidney Kimmel Comprehensive Cancer Center Site#106
state: Maryland
city: Boston
country: United States
facility: Massachusetts General Hospital Site#103
state: Massachusetts
city: Boston
country: United States
facility: Dana Farber Cancer Institute Site#104
state: Massachusetts
city: Ann Arbor
country: United States
facility: University of Michigan Rogel Cancer Center Site #113
state: Michigan
city: New York
country: United States
facility: Columbia University Irving Medical Center - Herbert Irving Pavilion Site#112
state: New York
city: Portland
country: United States
facility: Providence Portland Medical Center Site #118
state: Oregon
city: Portland
country: United States
facility: Oregon Health and Science University Site #122
state: Oregon
city: Philadelphia
country: United States
facility: University of Pennsylvania-Abramson Cancer Center
state: Pennsylvania
city: Houston
country: United States
facility: The University of Texas MD Anderson Cancer Center Site#111
state: Texas
city: San Antonio
country: United States
facility: START - South Texas Accelerated Research Therapeutics, LLC Site# 101
state: Texas
city: Fairfax
country: United States
facility: Virginia Cancer Specialists Site#102
state: Virginia
city: Lyon
country: France
facility: Centre Léon Bérard Service d'Oncologie Médicale Site#202
state: Rhone-Alpes
city: Marseille
country: France
facility: Hôpital de la Timone Site #201
city: Barcelona
country: Spain
facility: Institut Català d'Oncologia Badalona Site#240
city: Barcelona
country: Spain
facility: Hospital Universitari Vall d'Hebrón Servicio de Oncología, Sala coordinación UITM Site#243
city: Barcelona
country: Spain
facility: Hospital Universitari Germans Trias i Pujol
city: Barcelona
country: Spain
facility: Hospital Universitario Dexeus Site#241
city: Madrid
country: Spain
facility: Clinica Universidad de Navarra Madrid Site #242
city: Madrid
country: Spain
facility: Clínica Universidad de Navarra Site#242
city: Manchester
country: United Kingdom
facility: The Christie NHS Foundation Trust Site#220
state: England
city: Cambridge
country: United Kingdom
facility: Cambridge University Hospitals NHS Foundation Trust
city: Newcastle Upon Tyne
country: United Kingdom
facility: The Newcastle Upon Tyne Hospitals NHS Foundation Trust Site #221
city: Oxford
country: United Kingdom
facility: Churchill Hospital Site #224
Study officials:
References:
citation: Munck JM, Berdini V, Bevan L, Brothwood JL, Castro J, Courtin A, East C, Ferraldeschi R, Heightman TD, Hindley CJ, Kucia-Tran J, Lyons JF, Martins V, Muench S, Murray CW, Norton D, O'Reilly M, Reader M, Rees DC, Rich SJ, Richardson CJ, Shah AD, Stanczuk L, Thompson NT, Wilsher NE, Woolford AJ, Wallis NG. ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK. Mol Cancer Ther. 2021 Oct;20(10):1757-1768. doi: 10.1158/1535-7163.MCT-20-0909. Epub 2021 Jul 30.